VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 330 filers reported holding VALEANT PHARMACEUTICALS INTL in Q2 2017. The put-call ratio across all filers is 1.24 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2018 | $174,348,000 | +120.1% | 9,069,278 | +82.3% | 0.10% | +9.2% |
Q1 2018 | $79,213,000 | -64.2% | 4,975,689 | -53.3% | 0.09% | -64.3% |
Q4 2017 | $221,332,000 | +223.1% | 10,651,189 | +122.8% | 0.24% | +201.2% |
Q3 2017 | $68,505,000 | +64.8% | 4,780,500 | +99.0% | 0.08% | +52.8% |
Q2 2017 | $41,574,000 | -1.7% | 2,402,589 | -17.5% | 0.05% | -20.9% |
Q4 2016 | $42,294,000 | +298.3% | 2,913,089 | +573.6% | 0.07% | +252.6% |
Q3 2016 | $10,618,000 | +371.3% | 432,489 | +286.5% | 0.02% | +375.0% |
Q2 2016 | $2,253,000 | -90.6% | 111,889 | +3.8% | 0.00% | -92.7% |
Q2 2015 | $23,942,000 | -74.7% | 107,789 | -77.3% | 0.06% | -72.6% |
Q1 2015 | $94,465,000 | +1592.9% | 475,837 | +1120.4% | 0.20% | +1446.2% |
Q4 2014 | $5,580,000 | -10.3% | 38,989 | -17.4% | 0.01% | -13.3% |
Q1 2014 | $6,218,000 | -85.5% | 47,189 | -87.0% | 0.02% | -85.3% |
Q4 2013 | $42,756,000 | – | 364,189 | – | 0.10% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Brave Warrior Advisors | 5,701,010 | $1,266,479,000 | 36.57% |
Ruane, Cunniff & Goldfarb | 33,884,050 | $7,527,342,000 | 35.90% |
LeVasseur Capital Partners LLC | 188,804 | $41,943,000 | 34.97% |
Pershing Square Capital Management | 19,473,933 | $4,326,134,000 | 29.95% |
FARLEY CAPITAL L.P. | 141,020 | $31,328,000 | 24.16% |
Ratan Capital Management LP | 1,038,033 | $230,599,000 | 21.97% |
Marble Arch Investments | 1,069,000 | $237,478,000 | 20.47% |
Arrow Capital Management, LLC | 144,461 | $32,092,000 | 18.04% |
Tesuji Partners | 1,368,040 | $303,910,000 | 17.93% |
ValueAct Holdings | 14,994,261 | $3,330,975,000 | 17.54% |